From The Washington Post · · 1m 10s
FDA Requires GLP-1 Makers to Warn of Vision Loss Risk
FDA orders GLP-1 drug makers to alert patients about potential vision loss side effects.
In brief
FDA orders GLP-1 drug makers to alert patients about potential vision loss side effects. FDA mandates GLP-1 manufacturers to warn of increased vision loss risk from drugs like Ozempic and Wegovy. Originally reported by The Washington Post.
FDA mandates GLP-1 warning
The Food and Drug Administration requires manufacturers of GLP-1 medications to warn patients about increased risk of vision loss.
GLP-1 drugs linked to eye stroke
GLP-1 medications can cause non-arteritic anterior ischemic optic neuropathy, a rare condition where vision loss occurs due to lack of blood flow to the optic nerve.
NAION risk is very low
Experts say the absolute risk of NAION is extremely low, affecting about six in 100,000 patients.
FDA reviews studies and lawsuits
The FDA cited a 2024 study of 16,000 patients and numerous lawsuits alleging vision loss after GLP-1 use.
Drug companies respond
Eli Lilly, Novo Nordisk, and Sanofi state they will evaluate the FDA update and emphasize patient safety.
Patients advised to seek help
Patients should contact doctors immediately if experiencing vision symptoms and discuss continuing or stopping GLP-1 medications.
The key point
FDA mandates GLP-1 manufacturers to warn of increased vision loss risk from drugs like Ozempic and Wegovy.
